{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:34:10Z","timestamp":1791999250116,"version":"4.4.0"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:00:00Z","timestamp":1609200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis, a chronic inflammatory skin disease, negatively impacts patients\u2019 quality of life (QoL). This randomized, phase III, double\u2010blind, placebo\u2010controlled, multicenter study evaluated the efficacy and safety of brodalumab, a human anti\u2010interleukin\u201017 receptor A monoclonal antibody, in Korean patients with moderate to severe plaque psoriasis. Coprimary end\u2010points were the percentage of patients with 75% or more improvement in Psoriasis Area and Severity Index (PASI 75) and static Physician\u2019s Global Assessment (sPGA) success (score 0\/1) at week 12. Secondary end\u2010points included the percentage improvement from baseline in PASI score and proportion of patients with PASI 50\/75\/90\/100 responses. QoL was assessed with the Dermatology Life Quality Index (DLQI). Eligible patients were randomized to receive brodalumab 210\u00a0mg (N\u00a0=\u00a040) or placebo (N\u00a0=\u00a022) every 2\u00a0weeks (Q2W) at a 2:1 ratio for 12\u00a0weeks. Subsequently, all patients entered an open\u2010label extension phase and received brodalumab 210\u00a0mg Q2W until week 62. At week 12, the proportion of patients who achieved the coprimary end\u2010points, PASI 75 and sPGA success, was significantly higher in the brodalumab 210\u00a0mg Q2W group compared with the placebo group (92.5% vs 0%). At week 12, the mean\u00a0\u00b1\u00a0SD percentage improvement in the PASI score was 96.87\u00a0\u00b1\u00a06.01% in the brodalumab 210\u00a0mg Q2W group, which was maintained until study end (week 64). PASI 50\/75\/90 responses were achieved by 100% of patients receiving brodalumab 210\u00a0mg Q2W at weeks 6, 13, and 24, respectively; PASI 100 was achieved by 82.8% of patients at week 64. Brodalumab treatment rapidly improved DLQI scores. The most common treatment\u2010emergent adverse events were nasopharyngitis, upper respiratory tract infections, tinea pedis, and urticaria. Overall, treatment with brodalumab 210\u00a0mg Q2W resulted in a rapid and significant clinical benefit and was well tolerated in patients with moderate to severe plaque psoriasis in Korea.<\/jats:p>","DOI":"10.1111\/1346-8138.15733","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T03:13:30Z","timestamp":1609298010000},"page":"807-817","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double\u2010blind, placebo\u2010controlled study"],"prefix":"10.1111","volume":"48","author":[{"given":"Seong Jun","family":"Seo","sequence":"first","affiliation":[{"name":"Department of Dermatology Chung\u2010Ang University Hospital Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bong Seok","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chosun University Hospital Gwangju South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1121-2055","authenticated-orcid":false,"given":"Joo\u2010Heung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeyoun","family":"Jeong","sequence":"additional","affiliation":[{"name":"Clinical Development Department Kyowa Kirin Korea Co., Ltd. Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,12,29]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.82"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217"},{"key":"e_1_2_8_4_1","volume-title":"Global report on psoriasis","author":"World Health Organization","year":"2016"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.193906"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.6.761"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0007-0963.2004.05891.x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16332"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0075-1"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S67534"},{"key":"e_1_2_8_11_1","volume-title":"SILIQ\u2122 (brodalumab) prescribing information","author":"Food and Drug Administration"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14493"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.095"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.10.009"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13785"},{"key":"e_1_2_8_17_1","volume-title":"Kyntheum approved in the EU for the treatment of adults with moderate\u2010to\u2010severe plaque psoriasis"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109017"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2008.06.026"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16464"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.026"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01459.x"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00466-2"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S113683"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.178099"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.05.005"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.094"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.039"},{"key":"e_1_2_8_31_1","first-page":"361","article-title":"Depression and suicidality in psoriasis and clinical studies of brodalumab: a narrative review","volume":"104","author":"Koo J","year":"2019","journal-title":"Cutis"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1228872"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.024"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-00789-9"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.051"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2017.01.004"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16051"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.13202"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15733","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1346-8138.15733","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.15733","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T09:34:35Z","timestamp":1693388075000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.15733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,29]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/1346-8138.15733"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.15733","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,29]]},"assertion":[{"value":"2020-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}